A Study Looking at the Safety of Ontorpacept in Participants with Different Types of Cancers
A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Category & Conditions: Cancer
Medicine: ONTORPACEPT(ONTORPACEPT)
ClinicalTrials.gov Identifier (NCT): NCT02663518
Protocol ID: C4961001
PrintDownloadOpen Plain Language Summary Result: Click here